# Brian T Tsuji

List of Publications by Year
in descending order



| 63 | 3,459 | 159585 30 | 144013 57 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 67 | 67 | 67 | 3426 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiâ€infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy, 2019, 39, 10-39. | 2.6 | 545 |
| 2 | Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing. Pharmacotherapy, 2010, 30, 1279-1291. | 2.6 | 340 |
| 3 | Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 3783-3789. | 3.2 | 150 |
| 4 | Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. International Journal of Antimicrobial Agents, 2016, 48, 592-597. | 2.5 | 137 |
| 5 | Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 2051-2062. | 3.2 | 119 |
| 6 | Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii. Scientific Reports, 2017, 7, 45527. | 3.3 | 89 |
| 7 | Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. Journal of Antimicrobial Chemotherapy, 2018, 73, 462-468. | 3.0 | 86 |
| 8 | The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 5103-5112. | 3.2 | 85 |
| 9 | Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens. Scientific Reports, 2016, 6, 26233. | 3.3 | 82 |
| 10 | Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2015, 59, 2315-2327. | 3.2 | 76 |
| 11 | Synergistic combinations of polymyxins. International Journal of Antimicrobial Agents, 2016, 48, 607-613. | 2.5 | 71 |
| 12 | Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design. Antimicrobial Agents and Chemotherapy, 2013, 57, 2343-2351. | 3.2 | 68 |
| 13 | Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance. Antimicrobial Agents and Chemotherapy, 2016, 60, 3921-3933. | 3.2 | 66 |
| 14 | Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use. Clinical Infectious Diseases, 2014, 58, 139-141. | 5.8 | 60 |
| 15 | Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 1434-1442. | 3.0 | 60 |
| 16 | High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 60 |
| 17 | Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. Journal of Antimicrobial Chemotherapy, 2013, 68, 2311-7. | 3.0 | 58 |
| 18 | Alterations of Metabolic and Lipid Profiles in Polymyxin-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and bla <sub>NDM-5</sub> : Preparation for a Postantibiotic Era. MBio, 2017, 8, . | 4.1 | 50 |
| 20 | Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype. Antimicrobial Agents and Chemotherapy, 2008, 52, 1533-1537. | 3.2 | 46 |
| 21 | Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infectious Diseases and Therapy, 2015, 4, 391-415. | 4.0 | 45 |
| 22 | Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. Journal of Antimicrobial Chemotherapy, 2017, 72, 1415-1420. | 3.0 | 44 |
| 23 | Application of Pharmacokinetic-Pharmacodynamic Modeling and the Justification of a Novel Fusidic Acid Dosing Regimen: Raising Lazarus From the Dead. Clinical Infectious Diseases, 2011, 52, S513-S519. | 5.8 | 43 |
| 24 | Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2016, 60, 3913-3920. | 3.2 | 43 |
| 25 | Pharmacodynamics of colistin and fosfomycin: a â€˜treasure troveâ€™ combination combats KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2017, 72, 1985-1990. | 3.0 | 43 |
| 26 | Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii : pharmacodynamics of new dosing strategies. Journal of Antimicrobial Chemotherapy, 2016, 71, 3148-3156. | 3.0 | 36 |
| 27 | High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance inAcinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2017, 72, 153-165. | 3.0 | 36 |
| 28 | Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. Journal of Antimicrobial Chemotherapy, 2012, 67, 2182-2190. | 3.0 | 33 |
| 29 | In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2008, 62, 156-160. | 3.0 | 32 |
| 30 | New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 1381-1388. | 3.2 | 30 |
| 31 | Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2012, 56, 3712-3719. | 3.2 | 29 |
| 32 | Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2016, 48, 331-336. | 2.5 | 28 |
| 33 | Evolution of Staphylococcus aureus under Vancomycin Selective Pressure: the Role of the Small-Colony Variant Phenotype. Antimicrobial Agents and Chemotherapy, 2015, 59, 1347-1351. | 3.2 | 26 |
| 34 | Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 4151-4158. | 3.2 | 26 |
| 35 | Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutablePseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2016, 71, 3157-3167. | 3.0 | 26 |
| 36 | Impact of Two-Component Regulatory Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2012, 56, 3453-3456. | 3.2 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Comparable Efficacy and Better Safety of Double Î²-Lactam Combination Therapy versus Î²â€Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 24 |
| 38 | A combination of ceftaroline and daptomycin has synergistic and bactericidal activityin vitroagainst daptomycin nonsusceptible methicillin-resistantStaphylococcus aureus(MRSA). Infectious Diseases, 2017, 49, 410-416. | 2.8 | 23 |
| 39 | Concentration-dependent plasma protein binding: Expect the unexpected. European Journal of Pharmaceutical Sciences, 2018, 122, 341-346. | 4.0 | 23 |
| 40 | Rational Combinations of Polymyxins with Other Antibiotics. Advances in Experimental Medicine and Biology, 2019, 1145, 251-288. | 1.6 | 21 |
| 41 | Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2015, 70, 818-826. | 3.0 | 20 |
| 42 | Shifting Gears: The Future of Polymyxin Antibiotics. Antibiotics, 2019, 8, 42. | 3.7 | 20 |
| 43 | Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 2870-2880. | 3.2 | 18 |
| 44 | Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 1584-1591. | 3.2 | 18 |
| 45 | Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density. Diagnostic Microbiology and Infectious Disease, 2009, 64, 220-224. | 1.8 | 17 |
| 46 | Four Decades of Î²-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. Clinical Pharmacokinetics, 2019, 58, 143-156. | 3.5 | 15 |
| 47 | Impact of accessory gene regulator (agr) dysfunction on vancomycin pharmacodynamics among Canadian community and health-care associated methicillin-resistant Staphylococcus aureus. Annals of Clinical Microbiology and Antimicrobials, 2011, 10, 20. | 3.8 | 14 |
| 48 | Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2016, 48, 719-724. | 2.5 | 14 |
| 49 | New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 14 |
| 50 | Pharmacodynamics of dose-escalated â€˜front-loadingâ€™ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli. Journal of Antimicrobial Chemotherapy, 2017, 72, 2297-2303. | 3.0 | 14 |
| 51 | Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 13 |
| 52 | Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined Î²-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations. Antimicrobial Agents and Chemotherapy, 2016, 60, 1967-1973. | 3.2 | 11 |
| 53 | Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study. Infectious Diseases, 2019, 51, 287-292. | 2.8 | 9 |
| 54 | In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against Î²-lactamase-producing Escherichia coli in a hollow-fibre infection model. International Journal of Antimicrobial Agents, 2017, 49, 25-30. | 2.5 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision. International Journal of Antimicrobial Agents, 2021, 57, 106269. | 2.5 | 8 |
| 56 | Native valveProteus mirabilisendocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing. BMJ Case Reports, 2016, 2016, bcr2016215956. | 0.5 | 6 |
| 57 | Emergence of Polymyxin B Resistance Influences Pathogenicity in Pseudomonas aeruginosa Mutators. Antimicrobial Agents and Chemotherapy, 2015, 59, 4343-4346. | 3.2 | 5 |
| 58 | Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach. PLoS ONE, 2016, 11, e0156131. | 2.5 | 5 |
| 59 | Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model. International Journal of Antimicrobial Agents, 2018, 52, 114-118. | 2.5 | 5 |
| 60 | Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 4 |
| 61 | ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. JMIR MHealth and UHealth, 2020, 8, e20525. | 3.7 | 4 |
| 62 | Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression. Journal of Antibiotics, 2017, 70, 98-101. | 2.0 | 2 |
| 63 | 1325. Things that go Bump in the Night: Combating Klebsiella pneumoniae co-producing New Delhi metallo-beta-lactamase (NDM) and Mobile Colistin Resistance (MCR). Open Forum Infectious Diseases, 2020, 7, S673-S673. | 0.9 | 0 |